GSK573719: all 51 studies that test it

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of ExacerbationRecruitingNCT07192016Phase 4
• Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting BronchodilatorsRecruitingNCT07133880Phase 4
• Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass ExposureRecruitingNCT06571942Phase 4
• A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaRecruitingNCT05757102Phase 3
• To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPDCompletedNCT05535972Phase 4Results posted
• Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled AsthmaCompletedNCT04937387Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT04923347Phase 4Results posted
• Evaluation of Triple Therapy Using Magnetic Resonance Imaging in AsthmaActive, not recruitingNCT04651777Phase 3Results posted
• A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03478696Phase 4Results posted
• A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03478683Phase 4Results posted
• A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03474081Phase 4Results posted
• INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice DesignCompletedNCT03467425Phase 4Results posted
• Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With AsthmaCompletedNCT03012061Phase 2Results posted
• Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02729051Phase 3Results posted
• A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis SubjectsCompletedNCT02673619Phase 2Results posted
• Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02570165Phase 2Results posted
• Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary HyperhidrosisCompletedNCT02563899Phase 2Results posted
• Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.CompletedNCT02487498Phase 3Results posted
• Efficacy and Safety Study of QVA149 in COPD PatientsCompletedNCT02487446Phase 3Results posted
• A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02236611Phase 4Results posted
• A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT02207829Phase 3Results posted
• Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic ComponentCompletedNCT02164539Phase 2Results posted
• Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2CompletedNCT02119286Phase 3Results posted
• Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01957163Phase 3Results posted
• A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01817764Phase 3Results posted
• Long-term Safety Study for GSK573719 in JapaneseCompletedNCT01702363Phase 3Results posted
• Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPDCompletedNCT01491802Phase 3Results posted
• Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPDCompletedNCT01387230Phase 3Results posted
• A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01372410Phase 2Results posted
• An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study BCompletedNCT01323660Phase 3Results posted
• 24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary DiseaseCompletedNCT01316913Phase 3Results posted
• A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPDCompletedNCT01313637Phase 3Results posted
• 28-day Repeat Dose Study of GSK573719CompletedNCT01030965Phase 2Results posted
• A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 DaysCompletedNCT00732472Phase 2Results posted
• Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPDSuspendedNCT07541378Not applicable
• Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover StudyCompletedNCT06905483Phase 4
• Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart FailureCompletedNCT04522596Phase 4
• Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness StudyWithdrawnNCT03949842Phase 4
• Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled AsthmaWithdrawnNCT03376932Phase 3
• A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)WithdrawnNCT02731846Phase 3
• Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male SubjectsCompletedNCT01934153Phase 1
• A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy SubjectsCompletedNCT01691547Phase 1
• A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy VolunteersCompletedNCT01577680Phase 1
• Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal ImpairmentCompletedNCT01571999Phase 1
• Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.CompletedNCT01521390Phase 1
• QTc Study GSK573719+GW642444CompletedNCT01521377Phase 1
• Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy SubjectsCompletedNCT01128634Phase 1
• GSK573719 IV Enabling StudyCompletedNCT01110018Phase 1
• A Study of GSK573719 in Healthy Japanese Male SubjectsCompletedNCT01013974Phase 1
• Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese SubjectsCompletedNCT00976144Phase 1
• A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy VolunteersCompletedNCT00475436Phase 1

← GSK573719 overview